Please cite this article in press J.S.Venkatesh et al., Guardians Of Resistance: A Review Of Antimicrobial Stewardship And Impact Of Clinical Pharmacists, Indo Am. J. P. Sci, 2024; 11 (02).

1. Wise R, Hart T, Cars O, et al. AMR, BMJ, 1998, vol. 317 (pg. 609-10)

2. ECDC/EMEA Joint Technical Report the Bacterial Challenge: Time to React. A Call to Narrow the Gap between Multidrug-resistant Bacteria in the EU and the Development of New Antibacterial Agents, 2009

3. London N, Nijsten R, Mertens P, et al. Effect of antibiotic therapy on the antibiotic resistance of faecal Escherichia coli in patients attending general practitioners, J Antimicrob Chemother, 1994, vol. 34 (pg. 239-46)

4. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study, Lancet, 2005, vol. 365 (pg. 579-87)

5. Hillier S, Roberts Z, Dunstan F, et al. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study, J Antimicrob Chemother, 2007, vol. 60 (pg. 92-9)

6. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 2009, vol. 48 (pg. 1-12)

7. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on AMR in individual patients: systematic review and meta-analysis, BMJ, 2010, vol. 340 pg. c2096

8. Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria, Nature, 2011, vol. 476 (pg. 393-4)

9. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for the management of severe sepsis and septic shock: 2012, Crit Care Med, 2013, vol. 41 (pg. 580-637)

10. Ashiru-Oredope D, Sharland M, Charani E, et al. on behalf of ARHAI AMS GroupImproving the quality of antibiotic prescribing in the NHS by developing a new AMS Programme: Start Smart—Then Focus. J Antimicrob Chemother, 2012, vol. 67 Suppl 1(pg. i51-63)

11. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance AMS, Clin Infect Dis, 2007, vol. 44 (pg. 159-77)

12. Department of Health Health and Social Care Act 2008: Code of Practice for Health and Adult Social Care on the Prevention and Control of Infections and Related Guidance, 2008

13. Perez A, Doloresco F, Hoffman JM. ACCP: economic evaluations of clinical pharmacy services: 2001–2005, Pharmacotherapy, 2008, vol. 28 (pg. 285e-323e)

14. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients, Cochrane Database Systematic Rev, 2005 issue 4: CD003543

15. Mol PGM, Wieringa JE, NannanPanday PV, et al. Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis, J Antimicrob Chemother, 2005, vol. 55 (pg. 550-7)

16. Department of HealthSaving lives: reducing infection, delivering clean and safe care. Antimicrobial prescribing a summary of best practice, 2007

17. Department of Health and the Health Protection Agency Clostridium difficile infection: How to deal with the problem, 2008

18. Anonymous. 1999. Ten great public health achievements-United States, 1900-1999. Morb. Mortal. Wkly. Rep.48:241-243.

19. Armstrong, G. L., L. A. Conn, and R. W. Pinner. 1999. Trends in infectious disease mortality in the United States during the 20th century. JAMA281:61-66.

20. Davies, J. 1990. What are antibiotics? Archaic functions for modern activities. Mol. Microbiol.4:1227-1232.

21. De la Cruz, F., J. M. Garcia-Lobo, and J. Davies. 2002. Antibiotic resistance: how bacterial populations respond to a simple evolutionary force, p. 19-36. In K. Lewis, A. A. Salyers, H. W. Taber, and R. G. Wax (ed.), Bacterial resistance to antimicrobials. Dekker, New York, NY.

22. Davies, J. E. 1997. Origins, acquisition and dissemination of antibiotic resistance determinants. CIBA Found. Symp.207:15-27; discussion 27-35.

23. Hawkey, P. M. 1998. The origins and molecular basis of antibiotic resistance. Br. Med. J.317:657-660.

24. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.40:1058-1060.

25. Powers, J. H. 2003. Development of drugs for antimicrobial-resistant pathogens. Curr. Opin. Infect. Dis.16:547-551.

26. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis.38:1279-1286.

27. Tenover, F. C., and J. M. Hughes. 1996. The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA275:300-304.

28. Heather M. Arnold1, Scott T. Micek1, Lee P. Skrupky, Marin H. Antibiotic Stewardship in the Intensive Care Unit Kollef Semin Respir Crit Care Med 2011; 32(2): 215-227. DOI: 10.1055/s-0031-1275534

29. Ingram PR, Seet JM, Budgeon CA, Murray R. Point-prevalence study of inappropriate antibiotic use at a tertiary Australian hospital. Intern Med J. 2012; 42(6):719–21.

30. Wang JS, Bearman G, Edmond M, Stevens MP. Guarding the goods: An introduction to AMS. Clin Microbiol Newsl. 2012; 34(12):93-7.

31. Cooke FJ, Franklin BD, Lawson W, Jacklin A, Holmes A. Multidisciplinary hospital antibiotic stewardship: a West London model. Clin Govern Int J. 2004; 9(4):237–43.

32. Chiarello E. How organizational context affects bioethical decision-making: Pharmacists’ management of gatekeeping processes in retail and hospital settings. Soc Sci Med. 2013; 98:319–29.

33. Hand K. Antibiotic pharmacists in the ascendancy. J Antimicrob Chemother. 2007; 60 suppl 1:i73–6.

34. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008; 28(6):816–7.

35. Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. Pharmacotherapy. 2004; 24(11):1491–8.

36. Van Mil JWF, Schulz M, Tromp TFJ. Pharmaceutical care, European developments in concepts, implementation, teaching, and research: a review. Pharm World Sci. 2004; 26(6):303–11.
37. Safdar, N., and D. G. Maki. 2002. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med.136:834-844.

38. Harbarth, S., A. D. Harris, Y. Carmeli, and M. H. Samore. 2001. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin. Infect. Dis.33:1462-1468.

39. Monnet, D. L., L. K. Archibald, L. Phillips, F. C. Tenover, J. E. McGowan, Jr., and R. P. Gaynes. 1998. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modelling. Intensive Care AMR Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect. Control Hosp. Epidemiol.19:388-394.

40. Centers for Disease Control and Prevention. 1995. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morb. Mortal. Wkly. Rep. Recomm. Rep44:1-13.

41. Beezhold, D. W., S. Slaughter, M. K. Hayden, M. Matushek, C. Nathan, G. M. Trenholme, and R. A. Weinstein. 1997. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin. Infect. Dis.24:704-706.

42. Boyle, J. F., S. A. Soumakis, A. Rendo, J. A. Herrington, D. G. Gianarkis, B. E. Thurberg, and B. G. Painter. 1993. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J. Clin. Microbiol.31:1280-1285.

43. Lautenbach, E., W. B. Bilker, and P. J. Brennan. 1999. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect. Control Hosp. Epidemiol.20:318-323.

44. Rao, G. G., F. Ojo, and D. Kolokithas. 1997. Vancomycin-resistant gram-positive cocci: risk factors for faecal carriage. J. Hosp. Infect.35:63-69.

45. Fridkin, S. K., R. Lawton, J. R. Edwards, F. C. Tenover, J. E. McGowan, Jr., and R. P. Gaynes. 2002. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg. Infect. Dis.8:702-707.

46. Fridkin, S. K., R. Lawton, J. R. Edwards, F. C. Tenover, J. E. McGowan, Jr., and R. P. Gaynes. 2002. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg. Infect. Dis.8:702-707.

47. Rice, L. B., V. Lakticova, M. S. Helfand, and R. Hutton-Thomas. 2004. In vitro, anti-enterococcal activity explains associations between exposures to antimicrobial agents and the risk of colonization by multiresistant enterococci. J. Infect. Dis.190:2162-2166.

48. Hamilton, C. D., R. Drew, S. W. Janning, J. K. Latour, and S. Hayward. 2000. Excessive use of vancomycin: a successful intervention strategy at an academic medical centre. Infect. Control Hosp. Epidemiol.21:42-45.

49. May, A. K., S. M. Melton, G. McGwin, J. M. Cross, S. A. Moser, and L. W. Rue. 2000. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock14:259-264.

50. Quale, J., D. Landman, G. Saurina, E. Atwood, V. DiTore, and K. Patel. 1996. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin. Infect. Dis.23:1020-1025.

51. Dziekan, G., A. Hahn, K. Thune, G. Schwarzer, K. Schafer, F. D. Daschner, and H. Grundmann. 2000. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J. Hosp. Infect.46:263-270.

52. Graffunder, E. M., and R. A. Venezia. 2002. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother.49:999-1005.

53. Weber, S. G., H. S. Gold, D. C. Hooper, A. W. Karchmer, and Y. Carmeli. 2003. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis.9:1415-1422.

54. Bisognano, C., P. Vaudaux, P. Rohner, D. P. Lew, and D. C. Hooper. 2000. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother.44:1428-1437.

55. Venezia, R. A., B. E. Domaracki, A. M. Evans, K. E. Preston, and E. M. Graffunder. 2001. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J. Antimicrob. Chemother.48:375-381.

56. Harbarth, S., S. Cosgrove, and Y. Carmeli. 2002. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob. Agents Chemother.46:1619-1628.

57. Harris, A. D., T. B. Karchmer, Y. Carmeli, and M. H. Samore. 2001. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis.32:1055-1061.
58. Rifenburg, R. P., J. A. Paladino, S. C. Hanson, J. A. Tuttle, and J. J. Schentag. 1996. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am. J. Health Syst. Pharm.53:2054-2062.

59. Sunenshine, R. H., L. A. Liedtke, D. B. Jernigan, and L. J. Strausbaugh. 2004. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin. Infect. Dis.38:934-938

60. Lawton, R. M., S. K. Fridkin, R. P. Gaynes, and J. E. McGowan, Jr. 2000. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect. Control Hosp. Epidemiol.21:256-259.

61. Struelens, M. J. 2003. Multidisciplinary antimicrobial management teams: the way forward to control AMR in hospitals. Curr. Opin. Infect. Dis.16:305-307.

62. Knox, K., W. Lawson, B. Dean, and A. Holmes. 2003. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist-a UK perspective. J. Hosp. Infect.53:85-90.

63. Infectious Diseases Society of America. 1997. Hospital pharmacists and infectious diseases specialists. Clin. Infect. Dis.25:802.

64. Carmichael, J. M., M. B. O’Connell, B. Devine, H. W. Kelly, L. Ereshefsky, W. D. Linn, and G. L. Stimmel. 1997. Collaborative drug therapy management by pharmacists. American College of Clinical Pharmacy. Pharmacotherapy17:1050-1061.

65. Gattis, W. A., V. Hasselblad, D. J. Whellan, and C. M. O’Connor. 1999. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch. Intern. Med.159:1939-1945.

66. Leape, L. L., D. J. Cullen, M. D. Clapp, E. Burdick, H. J. Demonaco, J. I. Erickson, and D. W. Bates. 1999. Pharmacist participation in physician rounds and adverse drug events in the intensive care unit. JAMA282:267-270.

67. Gross, R., A. S. Morgan, D. E. Kinky, M. Weiner, G. A. Gibson, and N. O. Fishman. 2001. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin. Infect. Dis.33:289-295.

68. Weller, T. M., and C. E. Jamieson. 2004. The expanding role of the antibiotic pharmacist. J. Antimicrob. Chemother.54:295-298.
69. Khadem TM, Dodds Ashley E, Wrobel MJ. AMS: a matter of process or outcome? Pharmacother, apy, 2012, vol. 32 (pg. 688-706)

70. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series, J Antimicrobial Chemotherapy, 2007, vol. 59 (pg. 990-5)

71. Nathwani D, Sneddon J, Metcalfe A, et al. AMS in Scotland: impact of a national programme, antimicrobial Resist Infect Control, 2012, vol. 1 pg. 7

72. Health Protection Agency MRSA and C. difficile Infections Fall by a Third, 2010 http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2010PressReleases/100716MRSAandcdiffdownbyathird

73. Magedanz L, Silliprandi EM, dos Santos RP. Impact of the pharmacist on a multi-disciplinary team in an AMS program: a quasi-experimental study, Int J Clin Pharm, 2012, vol. 34 (pg. 290-4)

74. Thakkar K, Gilchrist M, Dickinson E, et al. A quality improvement programme to increase compliance with an anti-infective prescribing policy, J Antimicrob Chemother, 2011, vol. 66 (pg. 1916-20)

75. Malcolm W, Nathwani D, Davey P, et al. From intermittent antibiotic point prevalence surveys to quality improvement: experience in Scottish hospitals, Antimicrob Resist Infect Control, 2013, vol. 2 pg. 3

76. Brink, A.J.; Messina, A.P.; Feldman, C.; Richards, G.A.; Becker, P.J.; Goff, D.A.; Bauer, K.A.; Nathwani, D.; van den Bergh, D. Netcare AMS Study Alliance AMS across 47 South African Hospitals: An Implementation Study. Lancet Infect. Dis. 2016, 16, 1017–1025.

77. Gebretekle, G.B.; Haile Mariam, D.; Abebe Taye, W.; Mulu Fentie, A.; Amogne Degu, W.; Alemayehu, T.; Beyene, T.; Libman, M.; Gedif Fenta, T.; Yansouni, C.P.; et al. Half of Prescribed Antibiotics Are Not Needed: A Pharmacist-Led AMS Intervention and Clinical Outcomes in a Referral Hospital in Ethiopia. Front. Public Health 2020, 8.

78. Ohl, C., & Luther, V. (2011). AMS for inpatient facilities. Journal of Hospital Medicine, 6 Suppl 1, S4-15.

79. Wickens, H., Farrell, S., Ashiru-Oredope, D., Jacklin, A., & Holmes, A. (2013). The increasing role of pharmacists in AMS in English hospitals. The Journal of Antimicrobial Chemotherapy, 68 11, 2675-81.

80. MacDougall, C., & Polk, R. (2005). AMS Programs in Health Care Systems. Clinical Microbiology Reviews, 18, 638 – 656.

81. Garau, J., & Bassetti, M. (2018). Role of pharmacists in AMS programmes. International Journal of Clinical Pharmacy, 40, 948-952.

82. Blanchette, L., Gauthier, T., Heil, E., Klepser, M., Kelly, K., Nailor, M., Wei, W., & Suda, K. (2018). The essential role of pharmacists in antibiotic stewardship in outpatient care: An official position statement of the Society of Infectious Diseases Pharmacists. Journal of the American Pharmacists Association: JAPhA, 58 5, 481-484.

83. Broom, A., Plage, S., Broom, J., Kirby, E., & Adams, J. (2015). A qualitative study of hospital pharmacists and antibiotic governance: negotiating interprofessional responsibilities, expertise and resource constraints. BMC Health Services Research, 16.

84. Sneddon, J., Gilchrist, M., & Wickens, H. (2015). Development of an expert professional curriculum for antimicrobial pharmacists in the UK. The Journal of Antimicrobial Chemotherapy, 70 5, 1277-80.

85. Nampoothiri, V., Sudhir, A., Joseph, M., Mohamed, Z., Menon, V., Charani, E., & Singh, S. (2021). Mapping the Implementation of a Clinical Pharmacist-Driven AMS Programme at a Tertiary Care Centre in South India. Antibiotics, 10.

86. Acquisto, N., & Baker, S. (2011). AMS in the Emergency Department. Journal of Pharmacy Practice, 24, 196 – 202.

87. Chahine, E., El-Lababidi, R., & Sourial, M. (2015). Engaging Pharmacy Students, Residents, and Fellows in AMS. Journal of Pharmacy Practice, 28, 585 – 591.
88. Nampoothiri, V., Sudhir, A., Joseph, M., Mohamed, Z., Menon, V., Charani, E., & Singh, S. (2021). Mapping the Implementation of a Clinical Pharmacist-Driven AMS Programme at a Tertiary Care Centre in South India. Antibiotics, 10.